Showing all 5 results

Diabetes Market Analysis, Size, Trends | Europe | 2019-2025 | MedSuite

In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased significantly in value. Abbott received CE Mark approval for FreeStyle® Libre in September 2014 and for FreeStyle® 2 in October 2018. The company also launched FGM in the U.S. market in late 2017 and has expanded to numerous international


Diabetes Market Analysis, Size, Trends | 2019-2025 | MedSuite

Throughout this medical market research, we analyzed over 90 diabetes companies across 16 countries and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts. While this MedSuite report contains all the Global Diabetes Monitoring, Treatment and Drug Delivery data and analysis, each of the market segments


Diabetes Market Analysis, Size, Trends | United States | 2019-2025 | MedSuite (Includes 9 Reports)

In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased dramatically in value. The high level of growth was attributed to the commercial launch of FGM in late 2017. Abbott received FDA approval for FreeStyle® Libre in September 2017 and for FreeStyle® Libre 14 Day in July 2018. The


Diabetes Monitoring, Treatment and Drug Delivery Procedure Volume Analysis | United States | 2017-2023 | MedPro

The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are “ultra-long-acting” and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an “ultra-rapid-acting” insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.


Flash Glucose Monitoring Market Analysis | Europe | 2016-2022 | MedCore

The FGM system is made up of two components: a sensor and an electronic reader device that takes readings of glucose levels from the sensor. Sensors are worn on the back of the upper arm of patients for up to 14 days and inserted in a similar fashion as CGM sensors, with an adhesive to hold it in place. The reader component is manually placed over the sensor and after about a second, the reader displays a measurement of the patient’s glucose level, a historical trend of previous scans and the direction in which the glucose level is moving. A recent product update allows patients to use near-field communication (NFC) technology to substitute their smartphones as the reader component, eliminating the need to purchase the dedicated reader device. The FGM system is also factory calibrated which removes the need for routine fingersticks; something that is not available in current CGM systems. These features are popular with patients who cite “the pain, inconvenience and indiscretion” of fingersticking as the primary reasons for not managing their diabetes as efficiently and proactively as they should.